CXCL8 and colorectal cancer: Recent clinical trials have reported that fisetin (100 mg) supplements taken for seven consecutive weeks significantly reduced inflammation markers such as IL-8 and hs-CRP in colorectal cancer patients and that fisetin may be a novel complementary anti-tumor agent [63].